Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Molecular NeuroImaging specializes in neuroimaging research services for the pharmaceutical and biotech industries. The company focuses on developing novel radioligands as tools for human research to improve early diagnosis and accelerate drug development in neurodegenerative and neuropsychiatric disorders. Its expertise includes radioligand development, early-phase human drug trials, large-scale Phase II–IV clinical imaging trials, multi-center quantitative imaging studies, biomarker development, and core image processing laboratory services. MNI was acquired by inviCRO in February 2016 but continues to operate as a division within inviCRO with an expanded global reach.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Molecular NeuroImaging.